Addex Therapeutics Ltd

SWX:ADXN Stock Report

Market Cap: CHF 5.8m

Addex Therapeutics Management

Management criteria checks 2/4

Addex Therapeutics' CEO is Tim Dyer, appointed in Jan 2002, has a tenure of 23.42 years. directly owns 10.15% of the company’s shares, worth CHF586.76K. The average tenure of the management team and the board of directors is 8.3 years and 10 years respectively.

Key information

Tim Dyer

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure23.4yrs
CEO ownership10.1%
Management average tenure8.3yrs
Board average tenure10yrs

Recent management updates

Recent updates

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

May 11
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Nov 23
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Tim Dyer's remuneration changed compared to Addex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-CHF 5m

Sep 30 2024n/an/a

-CHF 13m

Jun 30 2024n/an/a

-CHF 12m

Mar 31 2024n/an/a

-CHF 11m

Dec 31 2023n/an/a

-CHF 3m

Sep 30 2023n/an/a

-CHF 5m

Jun 30 2023n/an/a

-CHF 9m

Mar 31 2023n/an/a

-CHF 15m

Dec 31 2022n/an/a

-CHF 11m

Sep 30 2022n/an/a

-CHF 22m

Jun 30 2022n/an/a

-CHF 21m

Mar 31 2022n/an/a

-CHF 19m

Dec 31 2021n/an/a

-CHF 15m

Sep 30 2021n/an/a

-CHF 13m

Jun 30 2021n/an/a

-CHF 13m

Mar 31 2021n/an/a

-CHF 11m

Dec 31 2020CHF 917kCHF 454k

-CHF 13m

Sep 30 2020n/an/a

-CHF 14m

Jun 30 2020n/an/a

-CHF 15m

Mar 31 2020n/an/a

-CHF 16m

Dec 31 2019CHF 709kCHF 429k

-CHF 15m

Sep 30 2019n/an/a

-CHF 13m

Jun 30 2019n/an/a

-CHF 12m

Mar 31 2019n/an/a

-CHF 6m

Dec 31 2018CHF 2mn/a

-CHF 2m

Compensation vs Market: Insufficient data to establish whether Tim's total compensation is reasonable compared to companies of similar size in the Swiss market.

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim Dyer (57 yo)

23.4yrs
Tenure

Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Dyer
Co-Founder23.4yrsno data10.15%
CHF 586.8k
Roger Mills
Chief Medical Officer & Director8.6yrsCHF 27.75kno data
Lénaic Teyssédou
Head of Finance8yrsno datano data
Mikhail Kalinichev
Head of Translational Science3.8yrsno datano data
8.3yrs
Average Tenure
57.5yo
Average Age

Experienced Management: ADXN's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Dyer
Co-Founder10.4yrsno data10.15%
CHF 586.8k
Roger Mills
Chief Medical Officer & Director8.4yrsCHF 27.75kno data
Jason Nunn
Independent Directorno dataCHF 34.60kno data
Isaac Manke
Independent Director7yrsCHF 34.60kno data
Raymond Hill
Non-Executive Director10yrsCHF 46.28k1.39%
CHF 80.3k
Vincent Lawton
Independent Chairman of the Board16.2yrsCHF 76.86k2.55%
CHF 147.5k
10.0yrs
Average Tenure
62.5yo
Average Age

Experienced Board: ADXN's board of directors are seasoned and experienced ( 10 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/04 19:17
End of Day Share Price 2025/06/04 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Addex Therapeutics Ltd is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter RothenaicherBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research